Страна: Ирландия
Език: английски
Източник: HPRA (Health Products Regulatory Authority)
OXYTETRACYCLINE BASIC
Norbrook Laboratories Limited
QJ01AA06
OXYTETRACYCLINE BASIC
300 Mg/Ml
Solution for Injection
POM
Bovine, Ovine, Porcine
Oxytetracycline
Antibacterial
Authorised
1994-02-10
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Alamycin LA 300 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active Substance: Oxytetracycline base 300 mg (as Oxytetracycline dihydrate) Excipients: Sodium Formaldehyde Sulphoxylate 4.0 mg For a full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle, pigs and sheep. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment and control of conditions caused by, or associated with, organisms sensitive to oxytetracycline including: _Bordetella bronchiseptica_ _Actinomyces pyogenes_ _Erysipelothrix rhusiopathiae_ _Pasteurella _spp. _Staphylococcus _spp. _Streptococcus _spp. Certain mycoplasma, rickettsiae, protozoa and chlamydia. Alamycin LA 300 may be used in the treatment and control of a wide range of common systemic, respiratory, urinary and local infections caused by oxytetracycline sensitive organisms. Specific indications for Alamycin LA 300 include: pasteurellosis, pneumonia, atrophic rhinitis, erysipelas, joint-ill, navel-ill, supportive therapy in bovine mastitis, ovine keratoconjunctivitis (pink-eye) and enzootic abortion in sheep. HEALTH PRODUCTS REGULATORY AUTHORITY ________________________________________________________________________________________________________________________ _Date Printed 21/12/2015_ _CRN 7022548_ _page number: 1_ 4.3 CONTRAINDICATIONS Do not dilute the Alamycin LA 300. Do not use in animals with known hypersensitivity to the active ingredient. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES No special warnings. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTION(S) FOR USE IN ANIMALS If concurrent treatment is administered use a separate injection site. Use of the product should be based Прочетете целия документ